Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28841284 | 0.89 | KDM4E (0.59) | AHRLMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL28841287 | 0.89 | KDM4E (0.59) | AHRLMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL8530864 | 0.89 | LMNA (0.47) | AHRLMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL8530861 | 0.89 | LMNA (0.47) | AHRLMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL145506 | 0.89 | CALM1 (0.64) | LMNAALDH1A1CALM1GAAHPGD | |
| SCHEMBL10031845 | 0.87 | AHR (0.46) | AHRALDH1A1CYP3A4RELAHPGD | |
| SCHEMBL16492000 | 0.87 | RELA (0.57) | AHRLMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL16489731 | 0.87 | RELA (0.57) | AHRLMNAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL16489741 | 0.87 | RELA (0.57) | AHRLMNAALDH1A1KDM4ECYP3A4 | |
| Ammonia Solution, Strong SCHEMBL9169933 | 0.87 | CALM1 (0.62) | LMNAALDH1A1CALM1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066571-B2 | Pattern forming method, under coating agent, and laminate | Oji Holdings Corporation (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20210147603-A1 | SELF-ASSEMBLY COMPOSITION FOR PATTERN FORMATION AND PATTERN FORMING METHOD | Oji Holdings Corporation (JP) | 2021-05-20 | — | — | US | disclosed |
| US-20200048491-A1 | PATTERN FORMING METHOD, UNDER COATING AGENT, AND LAMINATE | Oji Holdings Corporation (JP) | 2020-02-13 | — | — | US | disclosed |
| EP-2006352-A1 | LIQUID-CRYSTAL COMPOSITION AND LIQUID-CRYSTAL ELEMENT | Chisso Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066571-B2 | Pattern forming method, under coating agent, and laminate | LMNB2, MCM4, LMNB1 | AHR 4696/4885LMNA 159/4885ALDH1A1 2196/4885 |
| US-20200048491-A1 | PATTERN FORMING METHOD, UNDER COATING AGENT, AND LAMINATE | LMNB2, MCM4, LMNB1 | AHR 4696/4885LMNA 159/4885ALDH1A1 2196/4885 |
| US-20210147603-A1 | SELF-ASSEMBLY COMPOSITION FOR PATTERN FORMATION AND PATTERN FORMING METHOD | IAPP, SAMM50, MAN1B1 | AHR 4512/4885LMNA 3660/4885ALDH1A1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.